drugset / Trial / NCT03927157
Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma
RandomizedParallel-groupTriple-blindTreatment
Summary
A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma
Timeline
- Start
- 2019-06-14
- Primary completion
- 2024-05-24
- Completion
- 2024-08-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tezepelumab | Monoclonal antibody | 210 mg | Subcutaneous |